The US FDA Grants Fast Track Designation to Theriva Biologics’ VCN-01 as 1L Treatment of PDAC
Shots:
- The US FDA has granted fast-track designation to the company’s VCN-01 (IV) + CT (gemcitabine/nab-paclitaxel) for PDAC and previously received ODD
- The company’s VCN-01 is being evaluated in P-IIb (VIRAGE) study to treat metastatic PDAC; patient enrolment completion is anticipated in Q3’24
- VCN-01, an oncolytic adenovirus administered to over 80 patients in P-I and investigator-sponsored trials to treat PDAC (in combination with chemotherapy), HNSCC (with an immune checkpoint inhibitor), ovarian cancer (with CAR-T cell therapy), colorectal cancer, and retinoblastoma (by intravitreal injection)
Ref: Theriva Biologics | Image: Theriva Biologics
Related News:- BioLineRx Reports First Patient Dosing with Motixafortide in P-II Study for the Treatment of Pancreatic Cancer (PDAC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies. He can be contacted at connect@pharmashots.com
